Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1756-8722
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma ; volume:14 ; number:1 ; day:13 ; month:4 ; year:2021 ; pages:1-5 ; date:12.2021
Journal of hematology & oncology ; 14, Heft 1 (13.4.2021), 1-5, 12.2021

Creator
Mateos, Maria V.
Gavriatopoulou, Maria
Facon, Thierry
Auner, Holger
Leleu, Xavier
Hájek, Roman
Dimopoulos, Meletios A.
Delimpasi, Sosana
Simonova, Maryana
Špička, Ivan
Pour, Ludĕk
Kriachok, Iryna
Pylypenko, Halyna
Doronin, Vadim
Usenko, Ganna
Benjamin, Reuben
Dolai, Tuphan K.
Sinha, Dinesh K.
Venner, Christopher P.
Garg, Mamta
Stevens, Don A.
Quach, Hang
Jagannath, Sundar
Moreau, Philippe
Levy, Moshe
Badros, Ashraf Z.
Anderson, Larry D.
Bahlis, Nizar J.
Cavo, Michele
Chai, Yi
Jeha, Jacqueline
Arazy, Melina
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Richardson, Paul G.
Grosicki, Sebastian
Contributor
SpringerLink (Online service)

DOI
10.1186/s13045-021-01071-9
URN
urn:nbn:de:101:1-2021060220435964178053
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Mateos, Maria V.
  • Gavriatopoulou, Maria
  • Facon, Thierry
  • Auner, Holger
  • Leleu, Xavier
  • Hájek, Roman
  • Dimopoulos, Meletios A.
  • Delimpasi, Sosana
  • Simonova, Maryana
  • Špička, Ivan
  • Pour, Ludĕk
  • Kriachok, Iryna
  • Pylypenko, Halyna
  • Doronin, Vadim
  • Usenko, Ganna
  • Benjamin, Reuben
  • Dolai, Tuphan K.
  • Sinha, Dinesh K.
  • Venner, Christopher P.
  • Garg, Mamta
  • Stevens, Don A.
  • Quach, Hang
  • Jagannath, Sundar
  • Moreau, Philippe
  • Levy, Moshe
  • Badros, Ashraf Z.
  • Anderson, Larry D.
  • Bahlis, Nizar J.
  • Cavo, Michele
  • Chai, Yi
  • Jeha, Jacqueline
  • Arazy, Melina
  • Shah, Jatin
  • Shacham, Sharon
  • Kauffman, Michael G.
  • Richardson, Paul G.
  • Grosicki, Sebastian
  • SpringerLink (Online service)

Other Objects (12)

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma

Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial

Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone

Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Related objects